LiDCO Group Plc
17 June 2005


For Immediate Release                                           17th June 2005


                                LiDCO GROUP PLC

                           ("LiDCO" or "the Company")

                      Clinical Advisory Board Appointment

17th June 2005: LiDCO Group plc (AIM: LID), the cardiovascular monitoring
company, is pleased to announce that Professor David Bennett, has joined its
Clinical Advisory Board.

Professor Bennett was the Director of the Intensive Care Unit, St George's
Hospital for more than 25 years and is a member of the editorial board of
Intensive Care Medicine and Critical Care. One of his main research interests
has been the application of less invasive monitoring technologies to optimise
cardiovascular physiology and thereby improve outcomes in critically ill
patients. He was one of the (TA1) investigators using LiDCO's technology in the
recently presented St George's study entitled: 'Early goal directed therapy
reduces morbidity and length of hospital stay following high risk surgery.'

Dr Terry O'Brien, LiDCO's Chief Executive, commented: "I am delighted to welcome
Prof David Bennett to our Clinical Advisory Board. David is internationally
renowned for his pioneering work on  the application  of less invasive
cardiovascular monitoring  to improve outcomes and reduce costs associated with
the treatment of risk surgery patients."

Prof David Bennett commented: "I am very pleased to be associated with LiDCO and
their innovative technology which facilitates the rapid and accurate assessment
of cardiac function.  The use of this technology has allowed us to complete a
post operative study in high risk surgery patients in whom the targeting of
oxygen delivery has led to a 40% reduction in length of hospital stay"

For further information please contact:

LiDCO Group Plc
Terry O'Brien (CEO) terry@lidco.com                                020 7749 1500
Hugh McGarel-Groves (FD) hugh.mcgarel-groves@lidco.com

Buchanan Communications
Tim Anderson, Mary-Jane Johnson, James Strong                      020 7466 5000

Panmure Gordon
Grant Harrison                                                     020 7459 3600
Marcus Jackson

Notes for Editors

About LiDCO Plc

LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of
minimally invasive, computer-based hemodynamic monitoring equipment and
disposables used primarily for the management of critical care and
cardiovascular risk hospital patients. Use of LiDCO's technology has been shown
to significantly reduce the complications (particularly infections) and costs
associated with major surgery.  The technology was invented in the Department of
Applied Physiology based at St Thomas' Hospital, London where the Company
maintains a research base.

The Company's manufacturing facility is in Hoxton, London and its current
products are:

•    LiDCOplus and PulseCO monitors: computer-based platforms for displaying a
range of real-time, continuous hemodynamic parameters including cardiac output,
oxygen delivery and fluid volume;

•    LiDCO disposables: used in conjunction with the LiDCOplus Monitor
accurately determine cardiac output in a minimally-invasive manner.

Distribution Network:

The Company has now achieved registration of its products in 13 markets in
Europe, the USA, Brazil and Japan.  It sells direct to the NHS in the UK, and
through a worldwide network of specialty critical care distributors.

Background to the recently published clinical trial: Better than standard care -
(EGDT) improves outcome in high risk surgery patients:

The results of a major trial at St George's Hospital, London using LiDCO's
minimally invasive monitoring technology were presented during the 25th
International Symposium on Intensive Care and Emergency Medicine in Brussels
(21st to 25th March). The results have revealed the following:

a) Savings in the cost of treating patients amounting to an average of £4,000
per patient.  Extrapolated nationally, this would equate to a saving of £500
million per annum for the NHS

b) The monetary saving (£248,000) - resulted from 640 hospital days saved for 62
patients, an average of more than 10 bed days per patient

c) The savings in cost and hospital days were associated with a significant
reduction in medical complications (particularly infections - which were halved)
 through the use of LiDCO's minimally invasive technology to improve tissue
oxygen levels following surgery.



--------------------------


 (TA1)


                      This information is provided by RNS
            The company news service from the London Stock Exchange